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Abstract
BACKGROUND: In majority of cases of differentiated thyroid carcinoma (DTC), the ablative radioiodine treatment shows high 
efficacy. In a small number of patients, mechanism of selective iodine uptake by the DTC cells is insufficient and alternative 
methods of diagnosis and treatment are needed. As demonstrated in vitro, DTC cells show expression of somatostatin recep-
tors. Radiolabeled somatostatin analogs are widely used in the diagnosis of neuroendocrine tumors. The aim of the study 
was to evaluate the utility of peptide receptor scintigraphy with the use of 99mTc-EDDA/HYNIC-TOC in the diagnosis of DTC in 
patients with elevated thyroglobulin concentrations (Tg), negative WBS and no effect of the consecutive radioiodine therapies.
MATERIAL AND METHODS: Whole body scintigraphy as well as SPECT of neck and chest were performed 3 and 24 h after 
i.v. administration of 740 MBq 99mTc-EDDA/HYNIC-TOC. The obtained images were compared with other radionuclide and ra-
diological imaging methods. Forty-three patients with DTC after surgery and ablative radioiodine treatment with negative WBS 
and elevated Tg were qualified. Patients’ age: 18–83 years (mean 58.0).
RESULTS: SRS showed foci of tracer accumulation in 29 cases (67.4%). Sensitivity was 69.0% specificity 78.6%. SRS correctly 
identified local recurrence in 8 pts., metastatic lymph nodes in 19 pts., lung metastases in 12 pts. and bone metastases in 
5 pts. SRS showed high sensitivity in the detection of metastatic lymph nodes (100%) and bone metastases (83.3%) and lung 
metastases (63.2%). Positive SRS was found in pts. with higher Tg concentrations (130 ± 144 vs. 30 ± 54 ng/ml).
CONCLUSION: Scintigraphy with the use of the studied technetium-99m-labeled somatostatin analog is useful in the evaluation 
of patients with advanced DTC. It shows relatively good sensitivity and specificity but not high enough to be recommended as 
a routine imaging method. The role of somatostatin receptor scintigraphy in DTC is complementary to other imaging modalities. 
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Background
Prognosis in differentiated thyroid carcinoma (DTC) is generally 
good. In less than 20% of patients local recurrence and cervical 
lymph node metastases may occur after thyroidectomy and radi-
oiodine therapy (RIT). Distant metastases are found in 5–10% of pa-
tients; they are located mainly in lungs (57%) and bones (24%) [1]. 
About 10–15% of patients with DTC have recurrent disease and 
25–50% of patients with locally advanced or metastatic DTC become 
radioactive iodine (131I) (RAI)-refractory [2, 3].
Treatment efficacy is monitored by the measurement of thy-
roglobulin concentration (Tg). In case of elevated Tg RIT treatment 
is performed followed by the whole body scan (WBS) that is aimed 
at the identification of iodine-avid foci of DTC [4]. In about 30% of 
cases DTC cells lose the ability to concentrate iodine [3]. It is caused 
by the dedifferentiation of these cells and mutation of natrium-iodide 
symporter (NIS) gene that is responsible for the uptake of iodide 
ions into thyroid cells [5–8]. In the situation of elevated Tg and 
negative WBS other imaging modalities are warranted to detect the 
localization of DTC foci and evaluate possibility of other treatment 
options including surgery. 
For many years PET-CT using 18-fluoro-deoxyglucose (18F-FDG) 
has been successfully used in the detection of non-iodine avid 
DTC recurrence [9, 10]. Sensitivity of PET-CT in population of DTC 
patients with elevated Tg and negative WBS is estimated between 
69 and 95%, especially when performed in the conditions of TSH 
stimulation [11–16]. It is especially useful in patients with Tg con-
centrations above 10 mg/l [17]. 
Another proposed method to visualize non-iodine avid DTC 
foci is the somatostatin receptor scintigraphy (SRS). In the first 
publication on this issue, 4 DTC patients were reported in whom 
111-indium labeled octreotide (Octreoscan) was used. The scan 
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was positive in three of these cases [18]. In numerous later stu-
dies different percentage of positive scans was reported ranging 
from 30 to 100% [19–24].
Synthesis of new 99mTc-labeled somatostatin analog that had 
been carried out at the beginning of this century opened a new era 
of imaging. 99mTc-labeled compounds showed better diagnostic 
parameters associated with the preferable physical properties of 
99m-technetium in comparison to 111-indium [25–28]. The so-
matostatin analog, 99mTc- EDDA/HYNIC-TOC (Tektrotyd) showed 
good diagnostic performance in neuroendocrine tumors [29, 30], 
in medullary thyroid carcinoma [31] and some other tumors that 
express somatostatin receptors. The aim of our study was to 
evaluate diagnostic performance of 99mTc- EDDA/HYNIC-TOC in 
the diagnosis of DTC refractory to radioiodine therapy. 
Material and methods
Material
Patients with suspected dedifferentiation of DTC who presented 
with elevated Tg and negative WBS were qualified to somatostatin 
receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC. All patients had 
undergone total thyroidectomy and at least three courses of RIT. In 
concordance with local and European guidelines of DTC manage-
ment [32, 33], the first RIT activity was 60–90 mCi (2.2–3.3 GBq) de-
pending on the risk factors. As none of the qualified patients achieved 
complete remission, the courses of RIT were repeated with higher 131I 
activities, ranging from 90 to 150 mCi (3.3–5.5 GBq). The intervals be-
tween subsequent courses of RIT ranged from 6 to 12 months. RIT 
was performed in the conditions of endogenous TSH stimulation after 
withdrawal of L-thyroxin for at least 4 weeks. Between the courses of 
RIT, patients were treated with suppressive doses of L-thyroxin (TSH 
below 0.3 mU/dl). SRS was performed during L-thyroxin treatment, 
at least 6 weeks after recent RIT. 
The control group consisted of patients after total thyroidectomy 
due to medullary thyroid carcinoma who had SRS for the detection 
of recurrent disease but who were eventually classified as complete 
remission, based on the normal values of calcitonin and negative 
imaging at 2-years follow-up. The obtained SRS were retrospectively 
utilized as the “normal” image in subjects after thyroidectomy. 
Methods
SRS was performed with the use of 99mTc- EDDA/HYNIC-TOC 
(Tektrotyd) manufactured by Polatom (Poland). The labeling with 
99mTc obtained from Mo/Tc generator (Amersham Health) was per-
formed on-site in concordance with the manufacturer’s recommen-
dations (30 min incubation 80°C). The radiochemical purity was as-
sessed with two methods: reverse-phase chromatography and 
thin-layer chromatography and it ranged between 94.9 and 98.1%.
Each patient was given an i.v. injection of 20–25 mCi (740–925 
MBq) of 99mTc-EDDA/HYNIC-TOC. No adverse effects was observed 
after injection, including allergic reactions. 
Images were registered twice in each patient: 3 h and 24 h 
post injection. Image acquisition was performed using one of the 
dual-head gamma cameras: Varicam (Elscint, Israel) or Infinia 
Hawkeye 4 (GE Healtchcare, USA), equipped with low energy 
— all-purpose collimators. Acquisition parameters were equal for 
both scanners. Each imaging session consisted of planar whole 
body scans in anterior and posterior projections (bed movement 
speed 15 cm/min, 256 x 1024 matrix) and SPECT images of the 
neck and chest (60 projections, acquisition time 20 s per frame). 
In patients scanned with Infinia Hawkeye 4 gamma camera, com-
puted tomography for anatomical correlation were also acquired.
Images were interpreted by two experienced nuclear medicine 
specialists. Foci of increased tracer accumulation were reported, 
especially in the most probable location of DTC recurrence (thyroid 
bed, cervical lymph nodes, mediastinum, lungs and bones). The ob-
tained images were compared with other imaging methods used for 
verification of the findings: cervical ultrasonography (US), computed 
tomography (CT), magnetic resonance imaging (MR) performed not 
earlier than 3 months before and not later than 3 months after SRS. 
WBS used for the qualification of the patients to the study 
was performed using the same gamma cameras with the use of 
high-energy collimators. The WBS was registered 7–10 days after 
RIT with the use of 90–150 mCi (3.3–5.5 GBq). Negative WBS 
defined as no indication of pathologic iodine uptake attributed to 
remnant thyroid tissue of DTC recurrence or metastasis was used 
as a qualifying criterion in this study. 
Tg measurement was performed with the use of radioimmune 
assay Dynotest Tg-S (Brahms Diagnostics Berlin, Germany) under 
conditions of endogenous TSH stimulation. Tg concentration above 
2 ng/ml was regarded as elevated and considered as the second 
qualifying criterion in the study. 
Results
Forty-three (36 female and 7 male) patients were retrospectively 
analyzed. The diagnosis of DTC was made 3 to 17 years (median 
7 years) before SRS and was based on the histopathological evalu-
ation of the resected thyroid tumor. Histopathological types of DTC 
were distributed as follows: papillary carcinoma in 25 patients (58.1%), 
including 2 patients with follicular variant of papillary carcinoma, fol-
licular carcinoma in 11 subjects (25.6%), including one patient with 
insular carcinoma and oxyphilic carcinoma in 7 patients (16.3%). 
Patients’ age ranged from 18 to 83 years (mean 58.0 ± 15.9, 
median 60 years). 
The T stage in TNM classification at the diagnosis was: T1 in 
4 patients (15.3%), T2 in 9 pts. (34.6%), T3 in 2 pts. (7.7%) and T4 
in 13 pts. (50.0%). 
The N stage was estimated as N0 in 17 pts. (65.4%) and N1 
in 9 pts. (34.6%). In the remaining 17 subjects TNM classification 
was not available, particularly in patients who were operated on 
before 2000 outside large surgical centers. 
Stimulated Tg concentrations ranged from 0.57 to 523.9 ng/ml 
(median 38 ng/ml). Two patients with Tg below 2 ng/ml were excep-
tionally qualified to the study due to highly elevated anti-Tg antibod-
ies (aTg) suggesting a persistent disease despite normal Tg level. 
Prior to SRS, the patients had undergone from 3 to 9 courses of 
RIT with the cumulative activity of 300 to 1440 mCi (11.1–53.2 GBq), 
median 720 mCi (26.6 GBq). 
SRS showed pathological foci of 99mTc- EDDA/HYNIC-TOC 
accumulation in 29 patients (67.4%). SRS was negative in the 
remaining 14 patients (32.6%).
Comparison of the subgroups of patients with positive and 
negative SRS is presented in Table 1. In the subgroup with positive 
SRS mean Tg was higher than in the subgroup with negative SRS 
(p = 0.0164). In patients with oxyphilic carcinoma, SRS was more 
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frequently positive than in other histopathological diagnoses. No dif-
ference was noted between the subgroups with respect to patients’ 
age, time from diagnosis and RIT cumulative activity.
Local recurrence
Pathologic foci in the neck region were found in 16 pts. (37.2%). 
In 8 of them (18.6%) the lesion was located in the thyroid bed and 
was interpreted as local recurrence (Figure 1). In 7 cases local 
recurrence was confirmed using US and biopsy. The patients were 
referred to further surgical treatment. In one patient the lesion 
was not found with US but it disappeared after next two courses of 
RIT performed despite negative WBS. 
Lymph node metastases
In 11 patients (25.6%) pathologic foci in the neck outside thyroid 
bed were found in SRS: in the submandibular region (3 cases) in 
the posterior neck triangle (2 cases) and in the supraclavicular 
region (8 cases). In 10 cases these findings were positively veri-
fied using US and/or CT and in 8 cases metastatic character of 
the lesions was confirmed in fine-needle biopsy. The size of the 
metastatic lymph nodes varied from 7 to 24 mm. 
Focal mediastinal uptake was found in 13 patients (27.9%). In 
one of them the focus was noted only in SPECT image (not in the 
planar scan). Contrast-enhanced CT revealed pathologic lymph 
nodes in the areas indicated at the SRS in 9 of these cases. In 
2 patients the focus was verified as hypertrophic thymus. In 2 pa-
tients the CT did not disclose any pathologic finding in mediastinum, 
so the SRS was interpreted as false positive. 
Distant metastases
In 13 patients (30.2%) focal uptake in the lungs was found: in 
3 cases in form of a solitary focus, in 10 cases as multiple lesions. 
CT confirmed metastatic character of these findings in 12 patients. 
In 9 of them the metastases were greater than 10 mm. In the remain-
ing case, the lesion had morphology of primary pulmonary malig-
nancy and was finally diagnosed as pulmonary adenocarcinoma.
In 7 patients without pulmonary lesions at SRS, pulmonary 
metastases with the diameter of 2–6 mm were visualized at CT. In 
these cases SRS was interpreted as false negative. 
In general, pulmonary metastases were present in 19 pa-
tients (44.2%). SRS was true positive in 12 of them (Figure 2). 
Remaining data is presented in Table 2.
Bone metastases were detected in 6 patients (14.0%). Five 
of them were positive at SRS. The lesions were found in the skull 
(2 pts.), spine (3 pts.), ribs (2 pts.) and pelvis (1 patient). All these 
lesions were confirmed by bone scintigraphy, MR and/or PET-CT. 
In one case, the metastases were found in bone scintigraphy and 
MR, but not in SRS (false negative scan) (Figure 3). Follicular carci-
noma was predominant diagnosis in patients with bone metastases 
(4 out of 6 cases). 
In one patient a previously unknown cerebellar metasta-
sis was detected by SRS in a patient with multiple pulmonary 
metastases. 
In the statistical analysis of the entire group, the mean age 
was lower among patients with local recurrence in comparison 
with lymph node or distant metastases. Patients with bone metas-
tases had significantly higher Tg levels than patients with other DTC 
locations. Complete data is presented in Table 2. 
Table 1. Patients characteristics and comparison of selected parameters in the subgroup with positive and negative SRS
All patients Patients with positive SRS Patients with negative SRS p
n 43 29 14
Age (years)
median
58.0 ± 15.9
60
60.2 ± 16.0
61.5
53.9 ± 18.0
57
0.2078
Time from diagnosis (years)
median
8.1 ± 5.1
7
8.3 ± 5.1
6.5
7.8 ± 7.0
7
0.7914
Cumulative 131I activity [mCi]
median
653 ± 293
570
702 ± 274
690
562 ± 265
390
0.1203
Tg [ng/dl]
median
95 ± 127
38
130 ± 144
101
30 ± 54
8
0.0164
Papillary thyroid carcinoma 25
58.1%
16 
64.0%
9
36.0%
0.0838
Follicular thyroid carcinoma 11
25.6%
6
54.5%
5
45.4%
0.5758
Oxyphilic type 7
16.3%
6
85.7%
1
14.3%
0.0001
Figure 1. 62-year-old male patient with oxyphilic carcinoma. SRS 
detected local recurrence and metastatic supraclavicular lymph nodes 
on the left side
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SRS diagnostic performance
Number of positive and negative SRS in general and with re-
spect to different lesion locations is presented in Table 3. For the 
calculation of diagnostic performance parameters, control group 
was included in the table. 
Based on the presented data, following parameters of the 
studied SRS with the use of 99mTc-EDDA/HYNIC-TOC were cal-
culated: sensitivity 69.0%, specificity 78.5%, positive predictive 
Table 2. Comparison of different parameters in patients with different findings (mean ± standard deviation and median are presented)
n Age (years) Papillary  
carcinoma (n, %)
Tg  
[ng/ml]
Time since  
diagnosis (years)
Cumulative radioiodine 
activity [mCi]
All patients 43 58.0 ± 15.9
60
25
58.1%
95 ± 127
38
8.1 ± 5.1
7
653 ± 293
570
Pts. with local recurrence 8 46.4 ± 17.9
47*
5
62.5%
37.4 ± 37.8
19 ♦
7.7± 2.1
7
737 ± 243
630
Pts. with cervical lymph nodes mets 11 63.6 ± 15.4
68*
8
72.7%
86.6 ± 60.6
95 ♦♦
7.3 ± 7.1
7
611 ± 339
450
Pts. with mediastinal lymph node mets 12 68.6 ± 9.42
67**
5
41.7%
132 ± 139
105
7.4 ± 5.7
6
648 ± 258
585
Pts. with pulmonary mets. 20 64.6 ± 15.7
63***
11
55.0%
105 ± 126
78
5.9 ± 3.6
6
699 ± 336
600
Pts. with bone mets 6 68.7 ± 10.1
69****
2
33.3%
227 ± 199
142
6.7 ± 7.3
3
673 ± 260
630
*p = 0.0382; **p = 0.0019; ***p = 0.013; ****p = 0.0184; ♦p = 0.0205; ♦♦p = 0.0439
Table 3. Diagnostic performance of SRS in the studied group
(1) (2) (3) (4) (5) (6) (7)
SRS Patients  
with DTC
Control  
group
Local  
recurrence
Lymph node 
metastases
Pulmonary 
metastases
Bone  
metastases
n 56 43 13 8 19 19 6
True positive 29 29 0 8 19 12 5
True negative 11 0 11 48 34 36 50
False positive 3 1 2 0 3 1 0
False negative 13 13 0 0 0 7 1
Figure 2. Pulmonary and bone metastases (skull, pubic bone, right 
femoral bone) in a patient with Tg = 523 ng/ml
Figure 3. 60-year-old male patient. Mediastinal and hilar lymph node 
metastases was detected in SRS performed 24 h p.i. (left). The bone 
scan revealed additionally metastases in the right pelvic bone (right) 
that were not seen at SRS (false negative finding of bone metastases) 
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value 90.6%, and negative predictive value 45.8%. With respect to 
the histopathologic type of the disease, sensitivity and specificity 
were as follows: in papillary thyroid carcinoma sensitivity — 64.0%, 
specificity — 78.6%; in follicular carcinoma 54.5% and 84.6%; in 
oxyphilic carcinoma 85.7% and 84.6% respectively.
Discussion 
Somatostatin receptors are expressed in both in normal and 
malignant cells of the neuroendocrine origin [34]. The somatosta-
tin analog labeled with 99m-technetium, 99mTc-EDDA/HYNIC-TOC 
became commercially available in 2003, gradually substituting 
the 111-indium labeled analog — Octreoscan. The majority of 
clinical research on 99mTc-EDDA/HYNIC-TOC was focused on the 
neuroendocrine tumors. Gabriel et al. reported high sensitivity 
(88%) and specificity (94%) of this method in a group of 88 pa-
tients with neuroendocrine tumors except insulinoma [29]. High 
diagnostic utility in this clinical setting was confirmed by Chrapko 
et al. [30]. Similarly high diagnostic accuracy of another analog, 
99mTc-EDDA/HYNIC-TATE was found by authors from Cracow [35]. 
Some diagnostic utility of 99mTc-EDDA/HYNIC-TOC scintigraphy 
was also reported in patients with solitary pulmonary nodule [36]. 
In our center, more than 1000 SRS using 99mTc-EDDA/HYNIC-TOC 
were performed in recent 12 years. Majority of patients were referred 
for the diagnosis of neuroendocrine tumors. The second group of 
indications were thyroid tumors. SRS was performed only in highly 
selected patients with medullary thyroid carcinoma and in DTC 
in whom standard imaging methods failed to detect foci of the 
disease. Previously, we documented a relatively high diagnostic 
utility of 99mTc-EDDA/HYNIC-TOC in patients with asymptomatic 
hypercalcitoninemia in course of medullary thyroid carcinoma. The 
overall sensitivity was 79.5%, specificity 83.3%, positive predictive 
value 96.9% and negative predictive value 38.5% [31]. In current 
study, our experiences with this method in patients with DTC recur-
rence manifested by asymptomatic hyperthyroglobulinemia are 
summarized. In this group of patients the results were quite similar: 
sensitivity — 69.0%, specificity — 78.5%, positive predictive value 
— 90.6%, negative predictive value — 45.8%.
In a similar study performed in Innsbruck, sensitivity of SRS 
using 99mTc-EDDA/HYNIC-TOC was similar to that obtained in our 
study (66%). Comparison with PET with 18F-FDG in the same patient 
cohort showed its better performance in terms of lesion detection 
(sensitivity 87%) [16]. In our patient group not all patients were 
referred for a PET-CT study, so a head-to-head comparison was not 
possible. 
Diagnostic performance of 99mTc-EDDA/HYNIC-TOC may 
be also compared to 111-Indium-labeled compound. In earlier 
years several studies were published with inconsistent results. 
Sensitivity of 111In-octreotide (Octrescan) in patients with DTC 
ranged from 20% to 100% [20–23, 37–39]. Such a wide range of 
results was caused by different classification criteria, wide range of 
tumor stage, different levels of Tg and in some cases poor statisti-
cal quality due to low number of subjects. One of the most similar 
patient cohort was studies by Giammarile et al. [21]. Among 43 
patients with elevated Tg and similar distribution of histopathological 
diagnosis to our study (20 papillary thyroid carcinoma, 9 — fol-
licular, 8 — oxyphilic) 22 patients showed positive SRS (51%), i.e. 
less than in our study. Although comparison of two methods in two 
patient cohorts should not result in clear conclusions, in this case 
the favorable results obtained with 99mTc-EDDA/HYNIC-TOC can 
be easily supported. The main cause of this difference is physical 
characteristics of gamma radiation emitted by two radionuclides: 
99mTc and 111In. Apart from the image quality (spatial resolution) that 
is adversely affected by higher energy of 111In, this radionuclide 
may be safely used in lower doses than 99mTc due to much longer 
physical half-life of 67 h versus 6 h and higher dose equivalent [40]. 
Efficacy of SRS using 99mTc-EDDA/HYNIC-TOC was not in-
fluenced by patients’ age, time since diagnosis and cumulative 
radioiodine activity. There was however clear correlation with the 
stimulated Tg concentration. Patients with positive SRS had higher 
Tg values than those with negative SRS. The scan was rarely posi-
tive in patients with Tg below 10 ng/ml (11%). This finding can be 
compared with published results of PET using 18F-FDG. In a study 
performed on a PET scanner without CT also 11–13% patients with 
Tg of 10 ng/ml had positive 18F-FDG study [7]. However, in a study 
performed with the use of a hybrid PET/CT scanner this percentage 
was much higher — 43–53% [41, 42]. 
In the presented study, clinical utility of 99mTc-EDDA/HYNIC-TOC 
was demonstrated. It must be stressed that these results were ob-
tained on a highly selected group of patients showing signs of dedif-
ferentiation. Treatment options in this patient subgroup is limited. 
Radioiodine treatment is not effective any more leading to unneces-
sary radiation burden. Attempts to use chemotherapy did not show 
sufficient efficacy [43]. Radiation therapy is used sometimes but 
it is restricted only to localized process. In general, prognosis in 
patients with dedifferentiation is much worse than in uncomplicated 
DTC. 5-year survival in patients with pulmonary metastases is ca. 
60% if lesions are iodine-avid and only 30% in the absence of iodine 
uptake [44–46]. Among possible treatment options peptide receptor 
radionuclide therapy (PRRT) with somatostatin analogs labeled with 
beta-emitters could be an interesting option. The analogues labeled 
with beta-emitters (yttrium-90 or lutetium-177) were found to provide 
encouraging results in patients with disseminated forms of neuro-
endocrine tumors (NET) [47, 48]. Demonstration of somatostatin 
receptor expression by the means of SRS is a crucial criterion to 
qualify to such an experimental treatment. The results of PRRT 
in DTC in our center have been published elsewhere [49]. PRRT 
was generally well-tolerated but the outcome was rather poor in 
majority of cases of radioiodine-refractory DTC.
In summary, SRS using 99mTc-EDDA/HYNIC-TOC is useful in 
the detection of disease foci in patients with radioiodine-refractory 
DTC. The method shows acceptable sensitivity and specificity that 
is however not sufficient to recommend it as a routine imaging 
modality. Positive SRS is more likely to occur in patients with highly 
elevated thyroglobulin concentrations. SRS plays complementary 
role to other imaging techniques including PET/CT with 18F-FDG.
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